#Pharmaceuticals #WeightLoss #DiabetesMedication
us.cnn.com
Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 | CNN
Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and Rybelsus by up to half starting in 2027.
#OverTheCounter #Pharmaceuticals #FDA
www.cnbc.com
FDA chief Marty Makary says 'everything should be over-the-counter' unless drug is unsafe or addictive
FDA's Marty Makary: Everything should be over-the-counter unless it's unsafe or requires monitoring
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes "everything should be over-the-counter" unless a drug is unsafe, addictive or requires monitoring - doubling down on a push that some in the pharmaceutical industry have questioned.
#Pharmaceuticals #Onshoring #AffordableMedicine
www.breitbart.com
Exclusive -- Secretary Lutnick: $400 Billion of Pharma Manufacturing Coming Home to America
Four hundred billion dollars of pharmaceutical manufacturing is headed to the U. S. thanks to the Trump administration's policies, Commerce Secretary Howard Lutnick said Wednesday at a policy discussion hosted by Breitbart News.
#HealthCare #ConsumerSavings #Pharmaceuticals
www.cbsnews.com
TrumpRx: See the 43 drugs available on the Trump administration's new discounted drug site
Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics.
#AstraZeneca #pharmaceuticals #cancerresearch
uk.finance.yahoo.com
AstraZeneca profits jump by 40% amid strong demand for cancer drugs
Drugs giant AstraZeneca has notched up a 40% surge in annual profits and forecast further growth in earnings over the year ahead as it continues to put faith in strong demand for its cancer treatments.
#FDA #PublicHealth #Pharmaceuticals
markets.businessinsider.com
FDA intends to 'take action' against non-FDA-approved GLP-1 drugs
The U. S. Food and Drug Administration announced its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies - including Hims & Hers (HIMS) and other compounding pharmacies - as similar alternatives to FDA-approved drugs.
#Pharmaceuticals #DrugPricing #HealthCare
www.cbsnews.com
White House launches TrumpRx discounted drug site
Laura Doan is a fact checker for CBS News Confirmed. She covers misinformation, AI and social media.
The Trump administration launched its new TrumpRx prescription drug listing site late Thursday, part of a push by President Trump to offer lower direct-to-consumer drug prices.
W
#Pharmaceuticals #DrugPricing #HealthcarePolicy
www.wsj.com
Can Trump and Big Pharma Get the World to Pay More for Drugs?
President Trump claimed his 'most favored nation' policy would slash U. S. prescription costs. Krisztian Bocsi/Bloomberg
Americans pay about three times what other wealthy nations do for branded prescription drugs.
#Biotech #China #Pharmaceuticals
www.forbes.com
How China Became the Biotech Industry's Back-Office
Forbes contributors publish independent expert analyses and insights.
For years, public debate around U. S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing.
#Pharmaceuticals #DrugPricing #HealthcarePolicy
www.cnbc.com
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
Big pharma is grappling with the impact of new drug pricing deals with President Donald Trump and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
#Pharmaceuticals #DrugPricing #HealthcarePolicy
www.cnbc.com
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
Big pharma is grappling with the impact of new drug pricing deals with President Donald Trump and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
#Pharmaceuticals #Investment #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.
